Tag Archive for: clinical trials

The healthcare industry is acutely aware of the elevated compliance concerns involved with artificial intelligence and machine learning, and its governing organizations are taking swift action to address these challenges. In fact, the latest guidelines proposed by international regulatory organizations such as the FDA, European Union (EU), and European Medicines Agency (EMA) are poised to reshape the lifesciences industry, especially for clinical trials.

The company is putting a stop to a trial investigating what it calls the Opdualag combination, a pairing of Opdivo (nivolumab) and relatlimab, in patients with microsatellite stable metastatic colorectal cancer.

Clinical trials continue to experience a paucity of diversity, but it will take a multipronged approach to infuse DEI into research.

The importance of diversity in clinical research has gained significant recognition, driven by its potential to reduce healthcare disparities, enhance patient outcomes, enrich medical education, and broaden research methodologies. However, consistent underrepresentation of racial and ethnic minorities in clinical trials poses a barrier to the generalizability of research findings.

Several cancer vaccine candidates are flying through clinical trials with promising results. Unlike traditional vaccines that aim to prevent a disease from occurring, therapeutic cancer vaccines train the patient’s immune system, enabling T cells to patrol the body for cancer cells and destroy them.

Breakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to-administer option for millions of people, according to interviews with 10 scientists and company executives.

The blood-brain barrier: It’s neuroscience’s next frontier, and a presentation on Roche’s trontinemab at the Clinical Trials on Alzheimer’s Disease conference last month sparked new optimism that researchers might be getting close to breaking through it.   

Neurocrine Biosciences on Thursday announced that two of its candidates—from separate partnerships with Xenon Pharmaceuticals and Takeda—failed their respective Phase II studies in focal onset seizures and major depressive disorder.

In the third quarter, Gilead‘s growth in its HIV and oncology businesses was nearly completely offset by declining sales from its COVID-19 drug Veklury (remdesivir) and hepatitis C virus portfolio.

The robot can reposition a patient without interrupting the surgical procedure.